Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTV NASDAQ:FATE NYSEAMERICAN:LCTX NYSEAMERICAN:OSTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$10.39+3.7%$8.92$2.22▼$14.53$256.84M2.18387,679 shs60,259 shsFATEFate Therapeutics$2.42+2.3%$2.45$0.91▼$3.23$280.32M2.512.67 million shs307,849 shsLCTXLineage Cell Therapeutics$1.12+5.2%$1.23$0.95▼$2.09$277.97M1.511.30 million shs393,049 shsOSTXOS Therapies$1.51+1.7%$1.74$1.15▼$2.57$68.54M-0.83670,559 shs79,505 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics-5.07%-0.24%+4.34%-2.38%+243.51%FATEFate Therapeutics+1.72%-8.53%-2.48%+88.80%+101.71%LCTXLineage Cell Therapeutics-0.93%-4.50%-21.48%-29.80%-0.93%OSTXOS Therapies-1.33%-4.52%-33.93%-12.94%-19.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$10.39+3.7%$8.92$2.22▼$14.53$256.84M2.18387,679 shs60,259 shsFATEFate Therapeutics$2.42+2.3%$2.45$0.91▼$3.23$280.32M2.512.67 million shs307,849 shsLCTXLineage Cell Therapeutics$1.12+5.2%$1.23$0.95▼$2.09$277.97M1.511.30 million shs393,049 shsOSTXOS Therapies$1.51+1.7%$1.74$1.15▼$2.57$68.54M-0.83670,559 shs79,505 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics-5.07%-0.24%+4.34%-2.38%+243.51%FATEFate Therapeutics+1.72%-8.53%-2.48%+88.80%+101.71%LCTXLineage Cell Therapeutics-0.93%-4.50%-21.48%-29.80%-0.93%OSTXOS Therapies-1.33%-4.52%-33.93%-12.94%-19.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 2.83Moderate Buy$39.00290.16% UpsideFATEFate Therapeutics 2.29Hold$5.13117.16% UpsideLCTXLineage Cell Therapeutics 3.00Buy$6.25489.62% UpsideOSTXOS Therapies 2.75Moderate Buy$13.33800.90% UpsideCurrent Analyst Ratings BreakdownLatest OSTX, FATE, LCTX, and ARTV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026ARTVArtiva Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/14/2026LCTXLineage Cell Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/9/2026OSTXOS Therapies Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.007/9/2026OSTXOS Therapies Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.006/8/2026ARTVArtiva Biotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$41.006/8/2026FATEFate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.006/4/2026OSTXOS Therapies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/26/2026ARTVArtiva Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/19/2026FATEFate Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.005/19/2026FATEFate Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/19/2026OSTXOS Therapies Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $13.00(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$250K988.40N/AN/A$4.48 per share2.23FATEFate Therapeutics$6.32M43.55N/AN/A$1.80 per share1.31LCTXLineage Cell Therapeutics$14.56M18.15N/AN/A$0.19 per share5.58OSTXOS TherapiesN/AN/AN/AN/A($0.17) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva Biotherapeutics-$83.86M-$3.54N/AN/AN/AN/A-73.15%-62.74%8/5/2026 (Estimated)FATEFate Therapeutics-$136.32M-$1.09N/AN/AN/A-2,056.79%-58.89%-39.39%8/11/2026 (Estimated)LCTXLineage Cell Therapeutics-$63.53M-$0.12N/AN/AN/A-434.44%-89.36%-36.39%8/11/2026 (Estimated)OSTXOS Therapies-$28.75M-$0.79N/A2.39N/AN/AN/A-422.43%N/ALatest OSTX, FATE, LCTX, and ARTV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026FATEFate Therapeutics-$0.28N/AN/AN/A$1.37 millionN/A8/11/2026Q2 2026LCTXLineage Cell Therapeutics-$0.03N/AN/AN/A$1.84 millionN/A8/5/2026Q2 2026ARTVArtiva Biotherapeutics-$0.64N/AN/AN/AN/AN/A5/18/2026Q1 2026OSTXOS TherapiesN/A-$0.27N/A-$0.27N/AN/A5/13/2026Q1 2026FATEFate Therapeutics-$0.29-$0.26+$0.03-$0.26$1.49 million$1.30 million5/12/2026Q1 2026LCTXLineage Cell Therapeutics-$0.02-$0.03-$0.01-$0.03$3.60 million$1.73 million5/8/2026Q1 2026ARTVArtiva Biotherapeutics-$0.88-$0.95-$0.07-$0.95N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/ALCTXLineage Cell TherapeuticsN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A8.168.16FATEFate TherapeuticsN/A5.855.85LCTXLineage Cell TherapeuticsN/A6.896.89OSTXOS TherapiesN/A0.050.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/AFATEFate Therapeutics97.54%LCTXLineage Cell Therapeutics62.47%OSTXOS TherapiesN/AInsider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%FATEFate Therapeutics4.74%LCTXLineage Cell Therapeutics24.70%OSTXOS Therapies10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.72 million19.43 millionN/AFATEFate Therapeutics550116.56 million111.03 millionOptionableLCTXLineage Cell Therapeutics60249.30 million187.72 millionNot OptionableOSTXOS TherapiesN/A45.54 million40.85 millionN/AOSTX, FATE, LCTX, and ARTV HeadlinesRecent News About These CompaniesOS Therapies Ends At-The-Market Equity Sales ProgramJuly 29 at 5:30 PM | tipranks.comOS Therapies is a buy, this analyst saysJuly 15, 2026 | cantechletter.comCOS Therapies (NYSEAMERICAN:OSTX) Upgraded to "Strong-Buy" at Roth CapitalJuly 10, 2026 | marketbeat.comOS Therapies Corporate Event Calendar | AMEX:OSTXJuly 9, 2026 | benzinga.comOS Therapies: OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST ProgramJuly 8, 2026 | finanznachrichten.deOS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST ProgramJuly 8, 2026 | newsfilecorp.comNWhy OS Therapies Incorporated’s (OSTX) Stock Is Down 10.11%July 6, 2026 | aaii.comAOS Therapies: OS Therapies Third Quarter 2026 Corporate OutlookJuly 6, 2026 | finanznachrichten.deOS Therapies Third Quarter 2026 Corporate OutlookJuly 6, 2026 | newsfilecorp.comNOS Therapies: OS Therapies Appoints Dr. Craig Eagle to Board of DirectorsJuly 2, 2026 | finanznachrichten.deOS Therapies Secures Convertible Note Financing for ExpansionJuly 2, 2026 | tipranks.comOS Therapies Appoints Dr. Craig Eagle to Board of DirectorsJuly 2, 2026 | newsfilecorp.comNOS Therapies Provides U.S. Regulatory UpdateJune 30, 2026 | newsfilecorp.comNOS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine OsteosarcomaJune 26, 2026 | newsfilecorp.comNOS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic OsteosarcomaJune 8, 2026 | newsfilecorp.comNOS Therapies: OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic OsteosarcomaJune 2, 2026 | finanznachrichten.deOS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic OsteosarcomaJune 2, 2026 | newsfilecorp.comNOS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery WorldMay 29, 2026 | newsfilecorp.comNOS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”May 28, 2026 | businesswire.comOS Therapies to Attend Upcoming Medical, Financial and Industry ConferencesMay 26, 2026 | newsfilecorp.comNOS Therapies Reports First Quarter 2026 Financials and Provides Business UpdateMay 18, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOSTX, FATE, LCTX, and ARTV Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$10.39 +0.37 (+3.73%) As of 11:46 AM Eastern This is a fair market value price provided by Massive. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Fate Therapeutics NASDAQ:FATE$2.42 +0.06 (+2.33%) As of 11:46 AM Eastern This is a fair market value price provided by Massive. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Lineage Cell Therapeutics NYSEAMERICAN:LCTX$1.12 +0.06 (+5.19%) As of 11:46 AM Eastern This is a fair market value price provided by Massive. Learn more.Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.OS Therapies NYSEAMERICAN:OSTX$1.50 +0.03 (+1.69%) As of 11:46 AM Eastern This is a fair market value price provided by Massive. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Earnings Setup Puts Its AI Growth Story Back on Trial Again Circle’s IBM Patent Deal Could Redraw the Stablecoin Infrastructure Race Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters UnitedHealth Just Gave Wall Street a Clearer Turnaround Signal Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
